Relmada therapeutics appoints Dr. Max Kates to propel NDV-01 toward phase 3

Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026

AstraZeneca to unveil breakthrough cancer trial results at ESMO 2025

The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types

Dr. Jitendra Singh inaugurates 10th Annual "Cell and Gene Therapy" symposium

Several technologies for hemoglobinopathies are being transferred to commercial partners

Datroway delivers first-ever overall survival breakthrough in 1st-line metastatic triple-negative breast cancer without immunotherapy

Datroway becomes the first and only therapy to show overall survival benefit versus chemotherapy in this difficult-to-treat patient population

India invites applications under PRIP scheme to drive pharma-medtech innovation

Early stage projects of up to Rs. 9 crore eligible for up to Rs. 5 crore assistance and later stage projects of up to Rs. 285 crore eligible for up to Rs. 100 crore assistance

Nanavati Max, Uzbekistan’s NVRH forge alliance to advance healthcare and training

Amgen’s Phase III data supports FDA label expansion of Repatha

Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention

Pfizer agrees to slash prescription drug prices for Americans

Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%

FDA authorizes first eyeglass lenses to slow progression of pediatric Myopia

FDA authorization was based on two years of clinical study data demonstrating that Essilor Stellest lenses significantly slowed myopia progression compared to single-vision control lenses

Enhertu improved in invasive disease-free survival in early breast cancer in DB-05

Second positive Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting